Targeting Epidermal Growth Factor Receptor in the Management of Lung Cancer

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 101-109

  Mok, Tony S K ^a   Lee, Kirsty ^a   Leung, Linda ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84894482459     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.010     Document Type: Article

References (61)

1. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
2. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
3. S. Cohen The stimulation of epidermal proliferation by a specific protein (EGF) Dev Biol 12 1965 394 407
4. J. Mendelsohn Growth factor receptors as targets for antitumor therapy with monoclonal antibodies Prog Allergy 45 1988 147 160
5. C.A. Butts, D. Bodkin, E.L. Middleman, C.W. Englund, D. Ellison, and Y. Alam et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer J Clin Oncol 25 2007 5777 5784
6. R. Rosell, G. Robinet, A. Szczesna, R. Ramlau, M. Constenla, and B.C. Mennecier et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer Ann Oncol 19 2008 362 369
7. T.J. Lynch, T. Patel, L. Dreisbach, M. McCleod, W.J. Heim, and R.C. Hermann et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 2010 911 917
8. R. Pirker, J.R. Pereira, A. Szczesna, J. von Pawel, M. Krzakowski, and R. Ramlau et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
9. M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, and J.Y. Douillard et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J Clin Oncol 21 2003 2237 2246
10. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr, D. Prager, and C.P. Belani et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial Jama 290 2003 2149 2158
11. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, and C. Camps et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 2009 958 967
12. K. Tamura, I. Okamoto, T. Kashii, S. Negoro, T. Hirashima, and S. Kudoh et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) Br J Cancer 98 2008 907 914
13. A. Sutani, Y. Nagai, K. Udagawa, Y. Uchida, N. Koyama, and Y. Murayama et al. Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp Br J Cancer 95 2006 1483 1489
14. L.V. Sequist, D.W. Bell, T.J. Lynch, and D.A. Haber Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer J Clin Oncol 25 2007 587 595
15. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
16. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, and II. Wistuba et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers J Natl Cancer Inst 97 2005 339 346
17. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
18. J.Y. Han, K. Park, S.W. Kim, D.H. Lee, H.Y. Kim, and H.T. Kim et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung J Clin Oncol 30 2012 1122 1128
19. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, and H. Isobe et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
20. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, and J. Tsurutani et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
21. C. Zhou, Y.L. Wu, G. Chen, J. Feng, X.Q. Liu, and C. Wang et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
22. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, and E. Felip et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
23. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, and J. von Pawel et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
24. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu, E.H. Tan, V. Hirsh, and S. Thongprasert et al. Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 2005 123 132
25. E.S. Kim, V. Hirsh, T. Mok, M.A. Socinski, R. Gervais, and Y.L. Wu et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
26. K. Sugio, H. Uramoto, T. Onitsuka, M. Mizukami, Y. Ichiki, and M. Sugaya et al. Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations Lung Cancer 64 2009 314 318
27. T. Mok, J.J. Yang, and K.C. Lam Treating patients with EGFR-sensitizing mutations: first line or second line - is there a difference? J Clin Oncol 31 2013 1081 1088
28. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, and V. Miller et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1 J Clin Oncol 22 2004 777 784
29. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, and C. Manegold et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
30. R.S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B.E. Johnson, and A. Sandler et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
31. U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, and F. De Rosa et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation trial J Clin Oncol 25 2007 1545 1552
32. S. Tracy, T. Mukohara, M. Hansen, M. Meyerson, B.E. Johnson, and P.A. Janne Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255 Cancer Res 64 2004 7241 7244
33. B. Piperdi, Y.-H. Ling, G. Kroog, and R. Perez-Soler Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro J Clin Oncol (Meeting Abstracts) 22 2004 7028
34. T. Kimura, C. Mahaffey, B. Pryde, P. Mack, A. Davies, and D. Gandara et al. Apoptotic effects of the docetaxel ->OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells J Clin Oncol (Meeting Abstracts) 22 2004 7143
35. T. Li, Y.H. Ling, I.D. Goldman, and R. Perez-Soler Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 2007 3413 3422
36. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, and R.S. Herbst et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
37. T.S. Mok, Y.L. Wu, C.J. Yu, C. Zhou, Y.M. Chen, and L. Zhang et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 27 2009 5080 5087
38. Y.L. Wu, J.S. Lee, S. Thongprasert, C.J. Yu, L. Zhang, and G. Ladrera et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Lancet Oncol 14 2013 777 786
39. J.G. Aerts, H. Codrington, N.A. Lankheet, S. Burgers, B. Biesma, and A.M. Dingemans et al. A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study Ann Oncol 2013 Epub 2013 August 28, 10.1013/annonc/mdt34. Available from: www.annonc.oxfordjournals.org
40. D.H. Lee, J.S. Lee, S.W. Kim, J. Rodrigues-Pereira, B. Han, and X.Q. Song et al. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer Eur J Cancer 2013 Epub 2013 July 24, 10.1016/j.ejca.2013.06.035. Available from: www.ejcancer.com
41. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, and P. Fidias et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 2011 75ra26
42. H.A. Yu, M.E. Arcila, N. Rekhtman, C.S. Sima, M.F. Zakowski, and W. Pao et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 2013 2240 2247
43. Y. Zhang, X.Y. Li, Y. Tang, Y. Xu, W.H. Guo, and Y.C. Li et al. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer 81 2013 302 305
44. D. Jackman, W. Pao, G.J. Riely, J.A. Engelman, M.G. Kris, and P.A. Janne et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28 2010 357 360
45. M. Nishino, S. Cardarella, S.E. Dahlberg, D.M. Jackman, N.H. Ramaiya, and H. Hatabu et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors Lung Cancer 79 2013 283 288
46. J.E. Chaft, G.R. Oxnard, C.S. Sima, M.G. Kris, V.A. Miller, and G.J. Riely Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design Clin Cancer Res 17 2011 6298 6303
47. G. Oxnard, P. Lo, D. Jackman, M. Butaney, S. Heon, and B. Johnson et al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer J Clin Oncol (Meeting Abstracts) 30 2012 7547
48. K. Nishie, T. Kawaguchi, A. Tamiya, T. Mimori, N. Takeuchi, and Y. Matsuda et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations J Thorac Oncol 7 2012 1722 1727
49. K. Asami, T. Okuma, T. Hirashima, M. Kawahara, S. Atagi, and T. Kawaguchi et al. Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations Lung Cancer 79 2013 276 282
50. H.A. Yu, C.S. Sima, J. Huang, S.B. Solomon, A. Rimner, and P. Paik et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J Thorac Oncol 8 2013 346 351
51. A.J. Weickhardt, B. Scheier, J.M. Burke, G. Gan, X. Lu, and P.A. Bunn Jr et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer J Thorac Oncol 7 2012 1807 1814
52. S.B. Goldberg, G.R. Oxnard, S. Digumarthy, A. Muzikansky, D.M. Jackman, and I.T. Lennes et al. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors Oncologist 2013 Epub 2013 September 26, 10.1634/theoncologist. 2013-0168. Available from: www.theoncologist.org
53. N. Yoshimura, K. Okishio, S. Mitsuoka, T. Kimura, T. Kawaguchi, and M. Kobayashi et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed J Thorac Oncol 8 2013 96 101
54. L.V. Sequist, J.C. Yang, N. Yamamoto, K. OÊByrne, V. Hirsh, and T. Mok et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 2013 3327 3334
55. Y. Wu, C. Zhou, C. Hu, J. Feng, S. Lu, and Y. Huang et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung J Clin Oncol (Meeting Abstracts) 31 2013 8016
56. V.A. Miller, V. Hirsh, J. Cadranel, Y.M. Chen, K. Park, and S.W. Kim et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol 13 2012 528 538
57. H. Yasuda, S. Kobayashi, and D.B. Costa EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications Lancet Oncol 13 2012 e23 e31
58. Y. Janjigian, H. Groen, L. Horn, E. Smit, Y. Fu, and M. Wang et al. Activity and tolerability of afatinib (BIBW2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib J Clin Oncol (Meeting Abstracts) 29 2011 7525
59. S.S. Ramalingam, F. Blackhall, M. Krzakowski, C.H. Barrios, K. Park, and I. Bover et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer J Clin Oncol 30 2012 3337 3344
60. M. Kris, Z. Goldberg, P. Janne, D. Kim, R. Martins, and T. Mok et al. Dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for first- line treatment of EGFR-mutant or HER2- mutant or -amplified lung cancers Ann Oncol (Meeting Abstracts) 23 2012 12280
61. T. Mok, K. Nakagawa, R. Rosell, Y.L. Wu, C. Trygstad, and R.L. Capizzi et al. Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib versus gefitinib for advanced non-small cell lung cancer in patients with epidermal growth factor receptor activating mutations J Clin Oncol (Meeting Abstracts) 2013 31 TPS8123